Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma

Although epidermal growth factor receptor (EGFR) is often over-expressed in soft tissue sarcoma (STS), a phase II trial using an EGFR inhibitor gefitinib showed a low response rate. This study identified a new secondary resistance mechanism of gefitinib in STS, and developed new strategies to improv...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaochun, Goldstein, David, Crowe, Philip J., Yang, Mark, Garrett, Kerryn, Zeps, Nikolajs, Yang, Jia-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008301/
https://www.ncbi.nlm.nih.gov/pubmed/26909593
http://dx.doi.org/10.18632/oncotarget.7452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008301/
https://www.ncbi.nlm.nih.gov/pubmed/26909593
http://dx.doi.org/10.18632/oncotarget.7452

Ejemplares similares